Xintela
Xintela AB Interim Report January - March 2024
Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.
First quarter 2024 for the group
Income amounted to TSEK 299 (0).
Loss before tax totalled TSEK 11,372 (loss: 15,843).
Loss per share was SEK 0.02 (loss: 0.05).
First quarter 2024 for the parent company
Income amounted to TSEK 299 (0).
Loss before tax totalled TSEK 9,688 (loss: 10,403).
Loss per share was SEK 0.02 (loss: 0.03).
At March 31, 2024, the equity/assets ratio was 52 % (45).
Significant events in the first quarter of 2024
Xintela appoints Lucienne Vonk as Chief Scientific Officer. (February 19, 2024)
Significant events after the end of the period
Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses. (May 23, 2024)
The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports.
Datum | 2024-05-24, kl 08:00 |
Källa | MFN |
![](https://static.allaaktier.se/ads/hand-waving-2.png)